PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease ReportsPlasma cell neoplasms
MeSH D054219 - plasma cell neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D009370:Neoplasms by histologic type
0 Companies
0 Drugs
Success rate
D054219: 
Plasma cell neoplasms
1 Company
1 Drug
$
Success rate
D000075363:Immunoglobulin light-chain amyloidosis
0 Companies
0 Drugs
Success rate
D008258:Waldenstrom macroglobulinemia
24 Companies
5 Drugs
$
Success rate
D009101:Multiple myeloma
81 Companies
34 Drugs
$
Success rate
D010954:Plasmacytoma
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Bristol Myers SquibbIdecabtagene vicleucel Abecma  2021-08-18 $401 M Q4/23-Q3/24 
Clinical Trials
Historical Success Rate
Phase 1
77%
71/92
Phase 2
27%
32/117
Phase 3
9%
5/56
Approved: 1Overall Success rate: 2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Bristol Myers Squibb
Idecabtagene vicleucel,
Belantamab,
Mafodotin,
Nogapendekin alfa,
Iberdomide,
Marizomib,
Tanespimycin,
Calcium dobesilate,
Regramostim,
Terfenadine,
Vorhyaluronidase alfa,
Serine,
Sodium lactate,
Bevifimod,
LIRILUMAB,
Mezigdomide,
Muromonab-cd3,
Retaspimycin,
ULOCUPLUMAB,
URELUMAB,
Veltuzumab,
Microcrystalline cellulose,
Biib028,
Corticoids,
Reolysin,
Thromboprophylaxis,
Vp16,
Mln9708,
Hsct,
Imids,
Sdd,
Arm1,
Pcd,
Pelareorep,
Arm2,
Bolus,
Cc5013,
Cmab819,
Evidence,
Sominex
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use